Julian Naranjo, MD
Interventional Pain Medicine · Natchitoches, LANPI 1093700015
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,797 of the $10,770 with a category attached, or 81.7%. 41 manufacturers reported payments, led by Medtronic at 27.5% of the total. Reporting peaked in 2020 at $3,345 and has fallen 83.1% since, to $565 in 2025.
Across 353 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Scilex Pharmaceuticals Inc.$1K
- Curonix LLC$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$943
- Nevro Corp.$618
- Collegium Pharmaceutical, Inc.$551
- plus $4K from 35 others
Across 3 payments — averaging $81.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hikma Pharmaceuticals USA$84
- Purdue Pharma L.p.$84
- Endo Pharmaceuticals Inc.$77
What the payments were for
- Consulting fees$50%
- Travel & lodging$1,93618%
- Food & beverage$8,79782%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,770 in reported general payments places this provider in the 75th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 21 | $91,385 |
| Xtampza ErOxycodone Myristate | 97 | $80,013 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,981 | $68,433 |
| OxycontinOxycodone Hcl | 62 | $53,171 |
| ZtlidoLidocaine | 67 | $47,236 |
| RelistorMethylnaltrexone Bromide | 18 | $43,631 |
| MovantikNaloxegol Oxalate | 83 | $37,684 |
| Diclofenac Sodium | 437 | $28,206 |
| Nucynta ErTapentadol Hcl | 13 | $23,173 |
| Lidocaine | 181 | $22,514 |
| Fentanyl | 104 | $15,942 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 563 | $15,335 |
| LyricaPregabalin | 11 | $9,367 |
| Oxycodone Hcl | 430 | $8,900 |
| Morphine Sulfate ErMorphine Sulfate | 192 | $7,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er | $551 | $103,186110 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $1,081 | $47,23667 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $943 | $43,63118 claims |
| Redhill Biopharma Inc.Movantik | $205 | $37,68483 claims |
| PfizerLyrica | $162 | $9,36711 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine Hcl | $12 | $6,20162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Natchitoches
- Maged GuirguisNew Orleans$565K
- Suneil JollyKenner$107K
- John CefaluShreveport$71K
- Steve LeeSlidell$57K
- William WhyteShreveport$39K
- Paul HubbellMetairie$33K
- Ken EhrhardtHammond$22K
- Thomas BerryLacombe$21K
- Randall BrewerShreveport$19K
- Corey Ann ConnCovinton$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.